Sanofi Avoids Patent Cliff For Now, Returns to Growing Sales And Profits In Third Quarter
This article was originally published in The Pink Sheet Daily
Sanofi's Q3 sales grow by 10% and net income by 4.1% as Genzyme acquisition compensates for increasing generic competition to leading products.
You may also be interested in...
Sanofi says it will cut up to 900 jobs in France over the next three years to make its R&D operations there more efficient – that’s less than half the number foreshadowed in July by French trade unions and after the drug maker came under public pressure from the country’s left-wing government.
Unlike Pfizer and Eisai’s Fragmin (dalteparin), the new ultra-low-molecular-weight heparin does not appear to carry a hematoma risk.
Three years ago Sanofi didn’t know it was number one in emerging markets. Now the French pharma can’t talk enough about emerging markets – so what happened?